Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia
Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia
复制标题
DOI：
10.1176/appi.ajp.159.9.1596
复制
发表时间：
2002-09-01
影响因子：
17.7
通讯作者：
van Rensburg, SJ
中科院分区：
文献类型：
--
作者：
Emsley, R;Myburgh, C;van Rensburg, SJ
客观的。该研究调查了乙基二十碳五烯酸 (E-EPA) 作为附加治疗对慢性、严重精神分裂症的疗效和耐受性。方法：进行了一项为期 12 周的随机、平行组、双盲、安慰剂对照、固定剂量附加研究。 40 名经过至少 6 个月稳定抗精神病药物治疗后症状持续存在的患者，除了现有治疗外，还接受了 E-EPA 或安慰剂。结果。第 12 周时，E-EPA 组的阳性和阴性症状量表总分以及运动障碍评分的降低程度显着高于安慰剂组。结论：EPA 可能是精神分裂症的一种有效且耐受性良好的附加治疗方法。
Objective. The study investigated the efficacy and tolerability of ethyl-eicosapentaenoic acid (E-EPA) as add-on treatment in chronic, severe schizophrenia.Method: A randomized, parallel-group, double-blind, placebo-controlled, fixed-dose, add-on study was conducted over 12 weeks. Forty patients with persistent symptoms after at least 6 months of stable antipsychotic treatment received E-EPA or placebo, in addition to their existing treatment.Results. At 12 weeks, the E-EPA group had significantly greater reduction of Positive and Negative Syndrome Scale total scores and of dyskinesia scores than the placebo group.Conclusions: EPA may be an effective and well-tolerated add-on treatment in schizophrenia.